Clinical trials of PurEPA

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

<table>
<thead>
<tr>
<th>Trial</th>
<th>Treatments</th>
<th>Patients</th>
<th>Trials design and methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>PurEPA vs placebo</td>
<td>PurEPA 3 enteric coated capsules/d (0.9g EPA + DHA) versus placebo (Mixed TG 3 enteric coated capsules)</td>
<td>established Crohn's disease, in remission</td>
<td>Parallel groups double-blind Italy</td>
</tr>
<tr>
<td>Belluzzi , 1996</td>
<td>n=39/39 follow-up: 12 months</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

More details and results:

- omega-3 fatty acids for cardiovascular prevention in all type of patients at http://www.trialresultscenter.org/go-Q121
- omega-3 fatty acids for cardiovascular prevention in patients at low risk at http://www.trialresultscenter.org/go-Q124

References

Belluzzi, 1996: